The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.
ADC Therapeutics, a Switzerland-based cancer drug developer that was spun off by pharmaceutical firm AstraZeneca’s Spirogen subsidiary, closed its initial public offering at almost $268m yesterday.
The company had initially floated on Friday, pricing more than 12.2 million shares at $19 each, above the IPO’s $16 to $18 range, and increased the size of the issue from 10.3 million shares.
On their first day of trading, ADC’s shares opened at $30.00 and had risen to $31.14 at close of…
